Challenging the Conventional Wisdom Around Doxorubicin in Soft Tissue Sarcoma
- 12 June 2026
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2600502
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Thirty years from FDA approval of pegylated liposomal doxorubicin (Doxil/Caelyx): an updated analysis and future perspectiveBMJ Oncology, 2025
- Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trialThe Lancet Oncology, 2022
- Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2018
- Efficacy and Cardiotoxicity of Liposomal Doxorubicin-Based Chemotherapy in Advanced Breast Cancer: A Meta-Analysis of Ten Randomized Controlled TrialsPLOS ONE, 2015
- An overview of doxorubicin formulations in cancer therapyJournal of Cancer Research and Therapeutics, 2014
- Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx®) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomasEuropean Journal of Cancer, 2006
- Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancerAnnals of Oncology, 2004
- Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL®/CAELYX®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcomaEuropean Journal of Cancer, 2001
- Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.Journal of Clinical Oncology, 1995
- Combination chemotherapy with adriamycin and streptozotocin; I. Clinical results in patients with advanced sarcomaClinical Pharmacology & Therapeutics, 1976